(Q43698832)

26 November 2017

title

Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer (English)

1 reference

26 November 2017

Grossfeld GD

1

1 reference

26 November 2017

Chaudhary UB

2

1 reference

26 November 2017

Reese DM

3

1 reference

26 November 2017

Carroll PR

4

1 reference

26 November 2017

Small EJ

5

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

58

1 reference

26 November 2017

issue

2

1 reference

26 November 2017

page(s)

240-245

1 reference

STUDIES ON PROSTATIC CANCER

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Loss of androgen dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent androgen suppression in the management of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent androgen deprivation for clinically localized prostate cancer: initial experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

A pilot study of intermittent androgen deprivation in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent endocrine therapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Current status of intermittent androgen suppression in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent endocrine therapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901114-1

7 January 2021

10.1016/S0090-4295(01)01114-1

Identifiers

DOI

1 reference

26 November 2017

1 reference